This biotech firm has room to run despite surging nearly 500% in past year, Morgan Stanley says
The investment bank upgraded the pharma stock to overweight from equal weight.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
